Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2020 15:06 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
October 15, 2020 15:05 ET | Source: Zynerba Pharmaceuticals, Inc.

New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
October 08, 2020 08:32 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
October 08, 2020 08:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
September 17, 2020 13:55 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
September 14, 2020 06:55 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Provides Update on Recent Milestones

- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully...
September 10, 2020 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences

DEVON, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
August 10, 2020 06:45 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights

DEVON, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
August 06, 2020 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference

DEVON, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
July 22, 2020 06:50 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup

DEVON, Pa., July 22, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...